Clinical Trials · NCT03695237
A Study to Evaluate Leuprolide Acetate 45 mg 6-Month Formulation in Children With Central Precocious Puberty (CPP)
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- AbbVie
- Enrollment
- 45
- Start date
- Oct 2018
- Locations
- 18 sites, United States, Puerto Rico
- Primary endpoint
- Percentage of Participants With Suppression of Peak Gonadotropin-releasing Hormone Agonist (GnRHa)-Stimulated Luteinizing Hormone (LH) to Less Than 4 mlU/mL at Week 24